anesthesia and semaglutide Doctors warn some popular weight-loss drugs may raise risk of complications under Tirzepatide vs Semaglutide | Best

We interview the experts and compile patient-friendly articles

Regional Studies ACHIEVE-J (NCT06010004) evaluates orforglipron specifically in Japanese patients with type 2 diabetes, addressing potential population-specific differences in efficacy, safety, and dosing requirements that are important for regulatory submission in Japan

Causes of Late-Onset Nodules The development of late-onset nodules after dermal filler treatment can be attributed to several factors, including inflammatory reactions, infections, and the type of filler used

GPR40 has drawn much attention as a potential therapeutic target in managing patients with diabetes